USITC publishes initial determination in litigation dispute

STOCKHOLM, October 31, 2016 – An Administrative Law Judge of the United States
International Trade Commission (USITC) issued an initial determination (a first
decision) on October 27 in a litigation dispute with Varian Medical Systems.
The judge dismissed Varian’s infringement claims on patents related to imaging
enhanced radiotherapy and declared them not infringed by Elekta or invalid due
to prior art incorporated in patents exclusively licensed by Elekta.

He further stated that certain parts of Elekta’s radiotherapy solutions are
violating patents owned by Varian, predominantly related to algorithms used in
treatment planning software.

The judge’s initial determination is being analyzed and several grounds have
been identified on which to seek review of this initial determination before the
USITC.

Elekta has previously filed parallel proceedings at the US Patent and Trademark
Office, which have been instituted, to declare these patents invalid.
Preliminary analysis is that there is a reasonable likelihood of success in
these cases.

This initial determination of the USITC will be subject to procedural reviews
within the USITC before any final determination is reached, which will likely
last until the end of Elekta’s fiscal year 2016/2017.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Johan Andersson, Director Investor Relations, Elekta AB
Tel: +46 8 587 25 415, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to
the EU Market Abuse Regulation. The information was submitted for publication at
07:30 CET on October 31, 2016.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,600 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.